Revolutionizing prostate cancer diagnostics with 3d pathology and deep learning

Prostate cancer stands as a prevalent threat to men’s health, ranking second in cancer-related deaths in the United States.

Tralokinumab Controls Moderate-to-Severe AD Over the Long Term

Tralokinumab (Adbry) was approved by the FDA in December 2021 for adult patients with moderate-to-severe atopic dermatitis based on data from three of the ECZTRA

November 28, 2023

Key questions (and answers) about the historic approval of a CRISPR-based medicine

History just happened. For the first time, a regulator has cleared a treatment using CRISPR, the gene-editing technology, for patients. The regulator is the United

November 16, 2023

Madrigal seeks expedited approval for NASH treatment

Madrigal has sought a priority review of the NDA for resmetirom to treat nonalcoholic steatohepatitis with liver fibrosis. Credit: Nephron / commons.wikimedia.org. Madrigal Pharmaceuticals has

July 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.